Lung Cancer Clinical Trials in Baltimore

Showing 581-600 of 845 trials

Iloprost in Preventing Lung Cancer in Patients at High Risk for This Disease

NCT00084409

RATIONALE: Chemoprevention therapy is the use of certain drugs to try to prevent the development or recurrence of cancer. Iloprost may be effective in preventing lung cancer. PURPOSE: This randomized phase II trial is studying how well iloprost works in preventing lung cancer in patients who are at high risk for this disease.

Lung CancerPrecancerous Condition

University of Colorado, Denver152 participantsStarted Nov 2001

Aurora, Colorado, United States • Denver, Colorado, United States • Baltimore, Maryland, United States +3 more locations

COMPLETEDPhase 2< 1 mile

Study of Carboplatin/Paclitaxel With or Without Investigational Drug (CS-7017) in Subjects With Metastatic Non-small Cell Lung Cancer

NCT00806286

The study has a safety and a Phase 2 portion. In the safety portion of the study, subjects with metastatic non-small cell lung cancer will be treated with study drug (CS-7017) in combination with carboplatin and paclitaxel to evaluate safety. In the Phase 2 portion of the study, subjects will receive study drug (CS-7017) or placebo in combination with carboplatin and paclitaxel to evaluate effectiveness and safety. The study will find out if adding CS-7017 to carboplatin and paclitaxel will be safe and improve progression free survival in subjects with metastatic non-small cell lung cancer.

Metastatic Non-small Cell Lung Cancer

Daiichi Sankyo111 participantsStarted Dec 2008

Aurora, Colorado, United States • Washington D.C., District of Columbia, United States • Centralia, Illinois, United States +25 more locations

Iloprost in Preventing Lung Cancer in Patients at High Risk for This Disease

Study of Carboplatin/Paclitaxel With or Without Investigational Drug (CS-7017) in Subjects With Metastatic Non-small Cell Lung Cancer

Lung Cancer Trials in Other Cities

Lung-MAP: Rilotumumab and Erlotinib Hydrochloride or Erlotinib Hydrochloride Alone as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches

Trial Of Cisplatin And KML-001 in Platinum Responsive Malignancies

A Study of Rovalpituzumab Tesirine (SC16LD6.5) in the Frontline Treatment of Patients With Extensive Stage Small Cell Lung Cancer

A Phase 2 Study of Viagenpumatucel-L (HS-110) in Patients With Non-Small Cell Lung Cancer

A Trial of CV301 in Combination With Anti-PD-1 Therapy in Subjects With Non-Small Cell Lung Cancer

Mithramycin for Lung, Esophagus, and Other Chest Cancers

Testing a Spanish Version of a Patient Toxicity Questionnaire

A Study of Prexasertib (LY2606368) in Participants With Extensive Stage Disease Small Cell Lung Cancer

A Study of Atezolizumab as First-line Monotherapy for Advanced or Metastatic Non-Small Cell Lung Cancer

Phase 1b DV281 With an Anti-PD-1 Inhibitor in NSCLC

Cisplatin + Etoposide +/- Concurrent ZD6474 in Previously Untreated Extensive Stage Small Cell Lung Cancer

Bioequivalence & Food Effect Study in Patients With Solid Tumor or Hematologic Malignancies

Immunotherapy Study in Progressive or Relapsed Non-Small Cell Lung Cancer

A Phase 1b Study of Atezolizumab in Combination With Erlotinib or Alectinib in Participants With Non-Small Cell Lung Cancer (NSCLC)

S0720: Adjuvant Therapy Based on Gene Expression in Stage IA and IB Non-Small Cell Lung Cancer

S0709: Erlotinib With or Without Carboplatin and Paclitaxel in Stage IIIB or Stage IV Non-Small Cell Lung Cancer

S0635: Erlotinib and Bevacizumab in Stage IIIB and IV Bronchioloalveolar Carcinoma

Paclitaxel + Carboplatin With/ut BMS-275291 in Advanced or Metastatic Non-small Cell Lung Cancer

Other Conditions in Baltimore